Item 1B. Unresolved Staff Comments
Item 1B. Unresolved Staff Comments.
None.
Item 2. P r operties.
Our world headquarters is located in South Jordan, Utah, with our principal office for European operations located in Galway, Ireland and our principal office for Asian distribution located in Beijing, China. We also support our European operations from a distribution and customer service facility located in Maastricht, The Netherlands. In addition, we lease commercial space in India, Hong Kong, Italy, Dubai, Australia, Canada, Brazil, Malaysia, South Korea, Japan, South Africa, Singapore, Great Britain, Vietnam, Taiwan, New Zealand, Indonesia, and France, as well as in California and Texas. Our principal manufacturing and packaging facilities are located in Utah, Virginia, Texas, Ireland, Brazil, France, Singapore, Mexico, and The Netherlands. Our research and development activities are conducted principally at facilities located in Utah, California, Texas, Ireland, France, and Singapore.
Our total manufacturing, commercial, distribution, and research space is approximately 1.9 million square feet, of which approximately 1.0 million square feet is owned, and 0.9 million square feet is leased.
The following is a summary of the approximate square footage of our key facilities as of December 31, 2022:
Location
Main Purpose
Area (sq. ft.)
Utah
HQ, Manufacturing, Distribution, Research
724,170
Mexico
Manufacturing
196,690
Virginia
Manufacturing, Distribution
187,659
Ireland
Manufacturing, Research
139,680
The Netherlands
Manufacturing, Distribution
136,501
Texas
Manufacturing, Research
94,000
Singapore
Manufacturing, Research
68,000
China
Distribution
50,290
Operations associated with our cardiovascular segment utilize all of our facilities, while operations associated with our endoscopy segment are conducted primarily from our facilities located in Utah and Texas.
36
Table of Contents
We believe our existing and proposed facilities will generally be adequate for our present and future anticipated levels of operations.
Item 3. Legal Proceedings.
See Note 10 “Commitments and Contingencies” to our consolidated financial statements set forth in Item 8 of this report and incorporated herein by reference.
Item 4. Mine Safety Disclosures.
The disclosure required by this item is not applicable.
37
Table of Contents
PART II
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.